Meeting
2019 ASCO Annual Meeting
Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors.
Authors
Dana Backlund Cardin
Vanderbilt-Ingram Cancer Center, Nashville, TN
Dana Backlund Cardin , Haeseong Park , Jennifer Robinson Diamond , Alexander E. Drilon , Wendy L. VerMeulen , Xiaomin He , Hiroshi Hirai , Nital Soni , Jordan Berlin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Chemotherapy and Antibody-Drug Conjugates
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3031)
DOI
10.1200/JCO.2019.37.15_suppl.3031
Abstract #
3031
Poster Bd #
23
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.
First Author: Christian K. Kollmannsberger
Poster
2020 ASCO Virtual Scientific Program
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
First Author: Jasmine Huynh
Poster
2019 ASCO Annual Meeting
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
First Author: Nancy Chan
Poster
2018 ASCO Annual Meeting
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST).
First Author: Andrew J. Wagner